Inspire Medical Systems, Inc. — Form 8-K
Filed November 2, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 48/100
What the filing says
Inspire reported Q3 2026 revenue of $206.7M (down 7.9% YoY, +3.0% QoQ), diluted EPS of $(0.84), and adjusted diluted EPS of $0.14. The YoY decline was driven by coding/reimbursement headwinds. Key positive: AMA CPT Editorial Panel approved a new Category I CPT code for single-lead HGNS devices (including Inspire V) effective January 1, 2028. The company narrowed FY2026 guidance to $850–$860M revenue (vs. prior $835–$875M range) and $1.20–$1.40 adjusted diluted EPS. Project Horizon restructuring generated $30M in annualized growth investment capacity (~$25M in Q3 charges).
Why this rating
Revenue decline 7.9% YoY signals near-term pressure; CPT code approval is modest positive for 2028. Restructuring and narrowed guidance are ordinary course adjustments. Relative to $3.8B market cap, $206.7M quarterly revenue is baseline; $30M restructuring is <1% of cap. No transformational change.
See more from November 2, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.